COVID-19 seems to be less frequent and severe in children compared to adults. Despite the very few symptoms usually found in children, great attention was recorded when in April 2020 a hyperinflammatory process in children with fever and multiorgan involvement after a paucisymptomatic COVID infection was reported. The United States Centers for Disease Control and the World Health Organization recognized and defined this syndrome as “Multisystem Inflammatory Syndrome in Children (MIS-C).” We describe two cases of MIS-C presenting with fever, cutaneous rash, and a mild cardiac involvement expressed with a transient mitral valve involvement and a first-degree atrioventricular block. Acute treatment was managed with intravenous immunoglobulin, oral aspirin, and intravenous corticosteroids reaching consequent good outcome. Clinical characteristics, treatment management, follow-up, and long-term evolution of children with MIS-C are still poorly defined. Further research is needed to better understand the pathogenesis of this newly described condition, to validate a high-level recommended therapy and a specific therapy tapering timings.
【저자키워드】 COVID-19, Child, SARS–CoV−2, MIS-C multisystem inflammatory syndrome in children, heart involvement, 【초록키워드】 Corticosteroid, Treatment, Evolution, Intravenous immunoglobulin, therapy, Pathogenesis, children, Infection, Symptom, outcome, MIS-C, COVID, Adults, Characteristics, clinical, management, Fever, Research, Control, Mild, Aspirin, Follow-up, Rash, Multiorgan, intravenous, World Health Organization, Atrioventricular block, syndrome, center, Hyperinflammatory, mitral, defined, described, reported, United State, less, expressed, presenting, children with MIS-C, was recorded, 【제목키워드】 block, Involvement, Valve,